NeuroCME
CLINICAL CASECMECNE

Progressive Multiple Sclerosis: Why, When, and How to Help Slow or Even Improve Progression

Author(s)/Faculty: Harold Moses, MD
Release Date: 11/28/2017Expiration Date: 11/27/2018
Credit Type: CME / CNENumber of Credits: 0.25
Content Type: ArticleProvider: Vindico Medical Education
Multiple sclerosis (MS) is a chronic, often disabling disease that attacks the central nervous system. More than 2.3 million people are affected worldwide. MS begins in approximately 80% of patients as relapsing-remitting MS (RRMS). After 15 to 20 years, 50% to 60% of untreated RRMS patients transition to secondary progressive MS (SPMS), with progressive worsening of disability. Approximately 15% of patients are diagnosed with primary progressive MS (PPMS), which is associated with gradual disability accumulation from the onset. In this CME activity, an overview of progressive MS and the safety, efficacy, and utilization of current disease-modifying therapies (DMTs), will be discussed.